Home›Stock Screener›Aurobindo Pharma›Quarterly Results

Aurobindo Pharma Quarterly Results

Latest Quarter Net Profit
₹921 Cr
QMar 2026
Quarterly Results

Aurobindo Pharma quarterly results. In Mar 2026, Aurobindo Pharma (AUROPHARMA) reported revenue ₹8,869 Cr and net profit ₹921 Cr — revenue +4.1% YoY. Review Aurobindo Pharma P/E valuation to evaluate earnings-based valuation against sector peers.

AUROPHARMA Quarterly Results — Revenue, Profit & EPS Highlights

Aurobindo Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Check AUROPHARMA market cap trends to track the company's total market size over time.

  • Revenue of ₹8,869 Cr in Mar 2026 (-5.3% vs Jun 2026, +4.1% vs Mar 2025)
  • Net Profit of ₹921 Cr in Mar 2026 (-10.8% vs Jun 2026, +2.0% vs Mar 2025)
  • EBITDA of ₹1,766 Cr in Mar 2026 (-14.2% vs Jun 2026)
  • Operating Margin of 19.0% in Mar 2026 (-1.0pp vs Jun 2026)
  • Earnings Per Share of ₹15.86 in Mar 2026 (-11.2% vs Jun 2026)

Aurobindo Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS

AUROPHARMA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Mar 2026 Jun 2026 Sept 2025 Mar 2025 Jun 2025 QoQ YoY
Revenue (₹ Cr) 8,869 9,370 8,359 8,516 7,899 -5.3% 4.1%
Net Profit (₹ Cr) 921 1,032 848 903 824 - -
EBITDA (₹ Cr) 1,766 2,059 1,752 1,894 1,634 - -
EPS (₹) 15.86 17.86 14.61 15.56 14.20 - -
Operating Margin (%) 19.0% 20.0% 20.0% 21.0% 20.0% - -

AUROPHARMA Share Price Trend — 1-Year Movement Across Quarterly Results

Aurobindo Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Aurobindo Pharma share price chart.

Profitability Ratios

Profit Margin 10.4%
EBITDA Margin 19.9%
Operating Margin 19.0%
ROE (Annual) 9.7%

Balance Sheet Highlights

Total Assets ₹58,502 Cr
Total Equity ₹37,883 Cr
Current Assets ₹ Cr
Current Liabilities ₹2,580 Cr

Cash Flow Analysis

Operating Cash Flow ₹5,526 Cr
Investing Cash Flow ₹-2,630 Cr
Financing Cash Flow ₹-1,269 Cr
Net Cash Flow ₹1,628 Cr

Current Market Data

Current Price ₹1578.80
Exchange NSE
Last Updated Oct 21, 2026

Revenue Trend (₹ Cr)

Mar 2025 8,516
Sept 2025 8,359
Jun 2026 9,370
Mar 2026 8,869

Net Profit Trend (₹ Cr)

Mar 2025 903
Sept 2025 848
Jun 2026 1,032
Mar 2026 921

Operating Margin Trend (%)

Mar 2025 21.0%
Sept 2025 20.0%
Jun 2026 20.0%
Mar 2026 19.0%

AUROPHARMA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Aurobindo Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Mar 2026 		₹421,995.00 Cr 1745.1 15,018 2,710 -5.6% - 18.0% 154.4
Divis Laboratories
Mar 2026 		₹241,231.30 Cr 9190.0 2,986 751 -5.0% - 25.2% 324.6
Torrent Pharmaceuti…
Mar 2026 		₹188,719.51 Cr 4553.8 4,111 364 +27.7% +42.2% 8.9% 395.6
Laurus Labs
Mar 2026 		₹111,790.60 Cr 2012.5 1,823 282 -10.5% - 15.5% 389.3
Zydus Life Science
Mar 2026 		₹111,111.95 Cr 1117.3 7,569 1,341 -4.3% - 17.7% 88.3
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data

QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores